Chronic Myeloid Leukemia (CML) Clinical Trial
Official title:
Expanded Access Program of Ponatinib (AP24534) for Patients With Refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia
This protocol will allow expanded access of ponatinib to patients ≥18 years with chronic myeloid leukemia (CML) any phase or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) who have failed all available treatment options.
This protocol will allow expanded access of ponatinib to patients ≥18 years with CML or Ph+ALL who have failed all available treatment options. Patients with chronic (CP) or accelerated phase (AP) CML must be previously treated with and resistant or intolerant to imatinib, dasatinib and nilotinib or develop the T315I mutation after any tyrosine kinase inhibitor (TKI) therapy. Patients with blast phase (BP) CML and Ph+ ALL must be previously treated with and resistant or intolerant to imatinib and dasatinib or develop the T315I mutation after any TKI therapy. No formal analysis will be performed on any data obtained. Safety information will be collected and adverse events will be tabulated for reporting purposes only. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01066468 -
Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.
|
Phase 1 | |
Completed |
NCT00428909 -
Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
|
Phase 1 | |
Completed |
NCT04126707 -
The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans
|
Phase 1 | |
Active, not recruiting |
NCT02061800 -
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
|
Phase 1/Phase 2 | |
Completed |
NCT00488592 -
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
|
Phase 2 | |
Terminated |
NCT03615105 -
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
|
Phase 2 | |
Recruiting |
NCT02790515 -
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
|
Phase 2 | |
Active, not recruiting |
NCT03849651 -
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
|
Phase 2 | |
Completed |
NCT02363868 -
Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population
|
N/A | |
Withdrawn |
NCT01605981 -
Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.
|
Phase 4 | |
Completed |
NCT00433745 -
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
|
Phase 2 | |
Not yet recruiting |
NCT04709731 -
Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT03481868 -
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors
|
N/A | |
Recruiting |
NCT02889003 -
Second STOP After Pioglitazone Priming in CML Patients
|
Phase 2 | |
Completed |
NCT02733445 -
Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib
|
N/A | |
Active, not recruiting |
NCT03746054 -
Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality
|
Phase 3 | |
Completed |
NCT01667133 -
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
|
Phase 1/Phase 2 | |
Completed |
NCT00720785 -
Natural Killer Cells and Bortezomib to Treat Cancer
|
Phase 1 | |
Recruiting |
NCT05963061 -
Chronic Myeloid Leukemia (CML) Real-Life Database
|